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Flat cell cultures or xenografts are inadequate tools to unravel cancer complex biology.
3D in vitro tumor models garnered interest since they recapitulate better dynamic
mechanisms of cancer, but a gold standardmodel that faithfully mimics solid cancer is not
available yet. 3D breast cancermodel is fabricated using freeze-dried silk fibroin scaffolds.
Breast cancer cell lines (MCF-7 and MDA-MB231) are seeded with normal mammary
fibroblasts onto silk fibroin scaffold (1 and 2mm thick). Cells proliferation is monitored
by means of Alamar blue assay. 3D breast cancer models morphology is observed
by confocal microscopy. Gene expression modulation concerning extracellular matrix
markers is evaluated. Further, 3D bioengineered breast cancer models are treated with
doxorubicin. Silk fibroin scaffolds allow the proliferation of cancer cells and fibroblasts.
Cells growth is enhanced when cancer cells and fibroblasts are seeded together.
Histological staining shows 3D cell organization. MMP-1, MMP-2, MMP-3, Col-1, and
Fibronectin expression is upregulated in co-culture. After doxorubicin treatment, stronger
reduction in cell activity is observed in 2mm SF scaffold in comparison to 1mm. The
3D in vitro breast cancer model obtained can easily be scaled-up and translated to the
preclinical testing of novel chemotherapeutics.
Keywords: tumor stroma, silk fibroin, 3D cancer models, drug testing, tumor microenvironment
INTRODUCTION
Breast cancer is still a leading cause of death for the European women, especially in Eastern
Europe countries. European Commission report states that the death rate for breast cancer was
32.6 per 100000 inhabitants for women in 2014 (European Commission, 2016). Recent studies
predict that the number of breast cancer new cases will reach about 3.2 million per year by
2050 (Tao et al., 2015). A massive campaign has promoted prevention and awareness toward
this disease in the high-income country. Improved chemotherapeutic treatments are helping
to decrease the mortality rate for breast cancer (European Commission, 2016). However, the
incidence is increasing throughout Europe due to the spread of some risk factors as sedentary
lifestyle, obesity, increased average age of women having their first child and the reduced
number of child for each woman. Despite the progress in the chemotherapeutic treatment,
breast cancer remains the main cause of cancer-related deaths in Europe (Senkus et al., 2015).
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The challenge to defeat breast cancer is also related to the
understanding the complexity of the tumor microenvironment
(Soysal et al., 2015). Tumor “stroma” is an umbrella term that
takes into account the non-tumor cells and extracellular matrix
(ECM), while excluding probably the immune cells (Spill et al.,
2016). The interplay among different cell types imparts the
complexity to the disease (Stadler et al., 2015). Besides cancer
cells, the activated fibroblasts (well-known as myofibroblasts
or cancer activated fibroblasts, CAFs) are the key cellular
component of breast cancer stroma (Miles and Sikes, 2014). The
CAFs over-express several ECM proteins including collagens,
fibronectin and tenascin C that leads to the ECM stiffening
(Madar et al., 2013). The stiffer matrix prompts the invasion of
cancer cells into the surrounding tissues (Conklin and Keely,
2012; Klein-Goldberg et al., 2014). Hence, the reactive stroma
is actively involved in cancer progression. It is also considered
a key regulator of drug sensitivity of cancer cells as reported
by recent publications (Östman, 2012; Yuan et al., 2016; Fiori
et al., 2019; Qu et al., 2019). Though the research focus in
past decade involves the development of therapeutics targeting
tumor microenvironment, there is still a lack of understanding
how the tumor stromal architecture affect the response of
chemotherapeutics. Very limited is known about the relation
between cancer stromal architecture and response of anticancer
therapeutics, in space and time (Altrock et al., 2018). Hence, in
the present work we have employed scaffolds of various thickness
to engineer a 3D in vitro breast cancer model to investigate
the direct effect of scaffold thickness on tumorigenicity and
drug response. Silk protein fibroin scaffolds are already used to
develop tumor models of breast and hepatocarcinoma, which
serve as preclinical in vitro platform for drug testing (Talukdar
and Kundu, 2012; Kundu et al., 2013a). However, thesemodels do
not include the contribution of stromal cells such as fibroblasts or
the physical parameters like variable ECM thickness. It is already
mentioned that CAFs are of utmost importance for the tumoral
progression. An attempt is made to include fibroblasts in 3D in
vitro tumor model (Dondajewska et al., 2018). This model is used
as screening platform for chemotherapeutics. The breast cancer
model reported in the work is composed of murine cell lines.
It is known that mouse-derived cells cannot be considered as
relevant to human cells for the screening of chemotherapeutics
for human treatment. A heterotypic breast cancer model based
on silk fibroin scaffold is developed by incorporating epithelial
and fibroblast cells (Wang and Kaplan, 2012). The same group
also investigates the interaction among the breast cancer cells,
fibroblasts and adipose cells (Wang et al., 2010). Silk fibroin
is also used in combination with other biomaterials (Li et al.,
2018). Those breast cancer in vitro models can recapitulate the
complexity of the tumor microenvironment and the crosstalk
among the cells. In this work, we propose a heterotypic breast
cancer tumor model, which is obtained by seeding human
Abbreviations: CAF, Cancer associated fibroblasts; ECM, Extracellular
matrix; TGF-β, Tumor growth factor-β; TNF-α Tumor necrosis factor-
α; 2D, two-dimensional; 3D, three-dimensional; HMF, Human mammary
fibroblasts; 3D-BCM, Three-dimensional breast cancer model; SF, silk fibroin;
MMPs, metalloproteinases.
mammary fibroblasts and two different breast cancer cells lines
(MCF-7 and MDA-MB-231) on silk fibroin freeze-dried scaffolds
of two different thickness. The morphology and distribution
of the cells throughout the silk fibroin scaffolds are detected
by mean of scansion electron microscopy, hematoxylin and
eosin staining and confocal microscopy. The tumorigenicity
of these models are further compared by gene analysis. The
engineered 3D in vitro breast cancer model is then used as testing
platform using cancer drug doxorubicin. The results obtained
with homotypic and heterotypic cultures are then compared.
MATERIALS AND METHODS
Materials
Fresh mulberry silkworm (Bombyx mori) cocoons were obtained
from Portuguese Association of Parents and Friends of Mentally
Disabled Citizens (APPACDM, CasteloBranco, Portugal). All
other products are purchased from Sigma-Aldrich Company (St.
Lewis, USA), if not stated specifically.
Silk Fibroin Scaffold Preparation
Silk protein fibroin was extracted from the silk cocoons. The
cocoons after removing the pupae, were cut into pieces before
the degumming procedure. To remove glue protein sericin from
the silk fibers, the cocoon cut pieces were boiled in a solution
of 0.02M sodium carbonate for an hour. The silk fibers were
then washed three times with distilled water to remove sericin
residues (Talukdar and Kundu, 2012; Kundu et al., 2013a). Silk
fibers were dissolved in a solution of 9.3M lithium bromide for
1 h at 70◦C in an oven. The obtained silk fibroin (SF) solution was
dialyzed against distilled water for 48 h using benzoylated dialysis
tubing (MWCO: 2 kDa). The final concentration was obtained
by measuring the dry weight of SF solution after drying at 70◦C
in an oven for 24 h. 2 wt % (w/v) SF solution was poured into
each well of 96-well plate, which was serving as mold and frozen
at −20◦C for 48 h. Two different scaffold thicknesses (6mm in
diameter and 1 or 2mm thickness) were fabricated by pouring
50 or 100 µL of 2 wt% SF solution in each well, respectively.
SF scaffolds were obtained after freeze-drying (LyoAlfa 10/15,
Telstar, Spain).
Morphological Characterization
Micro-Architectures of 3D Scaffold
The non-porous “skin/ layer” formed at the top surface of
each scaffold was removed by simply peeling the skin away
immediately post-freeze-drying by using fine-forceps prior to
scanning electron microscopy analysis (Rnjak-Kovacina et al.,
2015). The morphology of the fabricated scaffold was analyzed
by mean of scanning electron microscopy (SEM) (JEOL JSM-
6010PLUS/LV). Before the observation, all the samples were
sputter-coated with a 3 nm layer of platinum (Sputter Coater
SC502, Cressington) and the micrographs were taken at an
accelerating voltage of 10 kV at different magnifications.
To confirm the interconnectivity of the scaffolds, X-ray
microtomography was performed (µCT1272, SkyScan 1272,
Belgium). The samples were scanned dry in air with a nominal
resolution of ∼2µm at an intensity of 200 µA, energy of
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50 kV and integration time of 1 s. NRecon programme was
used to reconstruct the 3D structure, which further investigated
morphometrically (CT Analyzer v1.17.0.0, SkyScan, Belgium) for
distribution of pores, porosity and pore wall thickness (n = 3)
(Arya et al., 2012).
Qualitative (Morphological) and Quantitative
Characterization: Diffusion
To illustrate the transport of biomolecules or therapeutics
within porous SF scaffolds, doxorubicin HCl (DOX, Carbosynth,
UK) was prepared in phosphate-buffered saline (PBS) at a
concentration of 1 mg/mL and the porous sponges were then
placed into the suspension. The diffusion phenomenon was
imaged immediately after soaking using an inverted confocal
microscope TCS SP8 (Leica Microsystems, Germany). The
images are represented as Z-stack maximum projection with
50µm of Z-size. To compare the loading and release ability of
scaffolds, they were immersed in doxorubicin HCl (500µg/mL
in PBS) and incubated overnight under continuous stirring at
37◦C (Cacicedo et al., 2016). The scaffolds were then taken
out and the concentration of DOX in supernatant was assayed
spectro-fluorometrically. The loading efficiency was evaluated
as follows:
DOX loading (%) = (DOXo− DOXs|DOXo) × 100
Where, DOXo = concentration of DOX at time zero, DOXs =
concentration of DOX in supernatant after incubation.
The release of DOX from silk fibroin scaffolds was monitored
as a function of time for 7 days in PBS at 37◦C. Cumulative
drug release was investigated by measuring doxorubicin-
associated fluorescence (excitation wavelength 485 nm, emission
wavelength 590 nm; Seib et al., 2013).
In vitro Cell Culture
Cells Types
Primary human mammary fibroblasts (HMF) were purchased
at Innoprot (Bizkaia, Spain) and grown in fibroblast culture
medium supplemented with 1% fibroblast growth factor, 1%
antibiotic/antimicotic and 2% FBS (Innoprot). MCF-7 andMDA-
MB-231 were purchased from ATCC (Virginia, USA) and
cultivated in DMEM high glucose (4.5 g/mL) (Sigma-Aldrich,
St. Lewis, USA), 10% (v/v) fetal bovine serum (FBS; Gibco, GB)
and 1% (v/v) antibiotic/antimycotic solution (final concentration
of penicillin 100 units/mL and streptomycin 100µg/mL; Gibco,
GB). The cells were cultured until 80% confluence at 37◦C in 5%
CO2 incubator.
Cell Seeding Onto 3D Silk Fibroin Scaffolds
After the freeze-drying process, the SF scaffolds were soaked
in ethanol to induce β-sheet crystallization and insolubility in
water (5min in absolute ethanol). To sterilize the scaffolds,
they were soaked in 70% ethanol for 30min. The scaffolds
were washed twice in sterile PBS 1X and sterilized by UV light
treatment before the seeding of cells under laminar hood. The
day before the seeding, the SF scaffold were transferred in 48
multi-well TCPS plate, soaked in the cell culture medium and
left overnight in the CO2 incubator. Confluent HMF, MCF-7
and MDA-MB231 were detached from the cell culture flasks
with TrypLE Express (1X) (Life Technologies, Carlsbad, CA,
USA). To carry out monoculture (HMF, MCF-7 and MDA-
MB-231), a suspension of 10 µL containing 2 × 105 of each
cell type was seeded on the entire top of each scaffold evenly.
The seeded scaffolds were allowed to adhere to the scaffold
for 3 h at 37◦C and 5% CO2 and then 500 µL of cell culture
medium was added in each well. Medium was changed each
3 days and ascorbic acid (50µg/mL) was added to the HMF
culture. The cultures were maintained for 14 days and samples
were collected for further analysis at different time point (Day
1, 3, 7, 9, 14). For co-culture models of breast cancer cells and
fibroblast, MCF-7 and MDA-MB231 were added at day 7 on
the previously HMF seeded scaffold. The density of HMF was
5 × 104 when the co-culture was carried out. To maintain 1:3
ratio between HMF and MCF-7 or MDA-MB-231, the cancer
cells were seeded at the density of 1.5x105 cells, at day 7 of the
culture. The constructs are referred as 3D-BCM (tridimensional
breast cancer model), namely as 3D-HMF, 3D-MCF7, 3D-231,
3D-HMF/MCF7, 3D-HMF/231. Moreover, we classify the 3D-
HMF, 3D-MCF7, 3D-231mono-culture with the term homotypic
and the 3D-HMF/MCF7, 3D-HMF/231 co-culture with the
term heterotypic.
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Cell Viability Assay
The cell viability in the 3D-BCM was assessed by Alamar blue
assay (Biorad). 3D-BCM at different time point (Day 1, 3, 7, 9, 14)
were incubated with 20% (v/v) Alamar blue solution in DMEM
High Glucose without FBS for 4 h at 37◦C. The fluorescence
was measured using a microplate reader (Synergy HT, BIO-
TEK) at an excitation wavelength of 530 nm and an emission
wavelength of 590 nm. SF scaffold without cells were used
as control.
Cell Morphology in the 3D Silk Fibroin
Scaffolds
Confocal Imaging
3D-BCMs were observed by mean of confocal laser microscopy
at different time points (1, 7, and 14 days). 3D-BCMs were
washed in PBS twice and fixed with 10% (v/v) neutral
buffered formalin (Richard-Allan Scientific
TM
, ThermoFisher
Scientific, Portugal) for 20min, permeabilized with 0.2% (v/v)
Triton X-100 for 15min. Actin microfilaments were stained
with Phalloidin–Tetramethylrhodamine B isothiocyanate
(1:200 in PBS; Sigma-Aldrich, USA) for 45min and nuclei
were counterstained with DAPI (1:1000 in PBS; Sigma-
Aldrich, USA) for 10min. The stained cells were observed by
inverted confocal microscope (TSC-SP8, Leica Microsystems,
Germany) with diode (405 nm) and HeNe (534 nm) lasers.
The samples were observed by using λex = 415 nm
and λem = 461 nm to observe cells’ nuclei fluorescence,
and using λex = 560 nm and λem = 630 nm to observe
actin filaments.
Scanning Electron Microscopy
The cell morphology in the 3D-BCM was observed at day
14 by mean of SEM. The constructs were washed in PBS
and fixed with a 2.5% (v/v) glutaraldehyde solution overnight
at 4◦C. Samples were further dehydrated through increasing
ethanol concentrations (30, 50, 70, 90, 100% v/v) for 1 h,
and left in ethanol absolute overnight. The samples were
undergone a cycle of critical point drying (Critical Point Dryer,
Autosandri-815, Series A, Tourisms). Before SEM observation,
all the samples were sputter coated with gold (Sputter Coater
FIGURE 1 | Schematic representation of the in vitro cell culture approach using silk protein fibroin (SF) biomaterial to obtain 3D breast cancer model. Silk fibroin
scaffolds of two different thicknesses support the growth of breast cancer cells co-cultured with mammary fibroblasts. The cancer cells were seeded 7 days after the
fibroblasts seeding. Four different co-cultured conditions were analyzed in this work: 3D-HMF/MCF7 in 1mm and 2mm SF scaffold, 3D-HMF/231 in 1mm and 2mm
SF scaffolds.
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SC502, Cressington) and the microphotographs were taken at an
accelerating voltage of 10 kV at different magnifications under
SEM (JEOL JSM-6010PLUS/LV).
Hematoxylin/Eosin Staining of Silk Fibroin-Cell
Scaffold Constructs
To investigate the cell distribution in the 3D-BCM,
hematoxylin/eosin staining was carried out. Briefly, the
constructs were washed twice in PBS 1X and fixed with 10%
(v/v) neutral buffered formalin (Richard Allan ScientificTM,
ThermoFisher Scientific, Portugal) for 20min. The samples were
maintained in PBS 1X, dehydrated through increasing ethanol
concentrations and embedded in paraffin using an automatized
process (EC350-2, Microm, Thermo Scientific, Waltham, MA,
USA). Successively, the samples were sectioned at a thickness of
7µm using a microtome (HM355S, Microm, Thermo scientific,
Portugal). Hematoxylin/eosin (Bio-optica, Italy) staining was
carried out according to manufacturer’s procedure through
an automatized process (HMS, Microm, Thermo Scientific,
Portugal). The stained structures were mounted with Entellan R©
(Inopat) and visualized under the microscope with an attached
camera (Leica DM750, Germany).
RNA Isolation and Real-Time RT-PCR
SF scaffolds with 1mm and 2mm thickness were seeded with
2x105 cells, as described in the section 2.4.2. 3D-BCMs were
collected at day 14 to investigate the mRNA expression of the
genes of interest. Total mRNAwas extracted using TRI Reagent R©
RNA Isolation Reagent (ThermoFisher Scientific, Portugal),
according to the manufacturer’s guidelines. RNA concentration
and purity were measured by mean of Nanodrop R© ND-1000
spectrophotometer (ThermoFisher Scientific, Portugal). The
synthesis of cDNA was carried out from 100 ng of mRNA using
qScriptTM cDNA Synthesis Kit (Quanta BioSciences, USA).
Briefly, a reaction mixture consisting of 4 µL qScript Reaction
Mix, 1 µL qScript Reverse Transcriptase (RT), RNA template
(100 ng total RNA) and nuclease-free water was prepared in 20
µL of final volume. The single-strand cDNA synthesis occurred
by incubating the complete reaction mixture for 5min at 22◦C,
followed by 30min at 42◦C and terminated with an incubation
of 5min at 85◦C. RT-PCR was performed using PerfeCTA R©
SYBR Green FastMix (Quanta BioSciences, USA), following
manufacturer’s instructions, on RT-PCR Mastercycler Realplex
machine (Realplex, Eppendorf, Germany). Primer sequences
(Eurofins Genomics, UK) were designed using Primer-BLAST
tool (Table 1). Livak’s method (211Ct) was used to quantify
the relative gene expression (Livak and Schmittgen, 2001). The
mRNA expression was first normalized to the average expression
of multiple internal control genes [glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) and β-actin (ACTB)]. Three samples of
each condition were considered and the results are represented as
fold change toward the gene expression in the 3D-HMF.
Drug Testing and Cytotoxicity on 3D-BCM
Scaffolds with 1 and 2mm thickness were seeded with 2 × 105
cells, as described in the section Cell Seeding Onto 3D Silk
Fibroin Scaffolds. At day 14, 3D-BCMs (3D-HMF, 3D-MCF7,
3D-231, 3D-HMF/MCF7; 3D-HMF/231) were treated with 15
and 30µg/mL of DOX (Carbosynth, UK). After the DOX treating
for 24, 48, and 72 h at 37◦C and 5% CO2, metabolic activity
and cell proliferation were assayed. To evaluate the metabolic
activity of the cells in the 3D-BCMs after doxorubicin treatment,
Alamar blue assay was performed according to the protocol
described in the section Cell Viability Assay. To evaluate cell
proliferation in the 3D-BCM after DOX treatment, the amount
of DNA of each was quantified by Quant-iTTM PicoGreen R©
dsDNA assay (Thermofisher scientific, Portugal), according to
the manufacturer’s guidelines. At each time point, the 3D-BCMs
used for the Alamar blue assay were washed twice with PBS,
incubated in 1ml of ultrapure water for 1 h at 37◦C and kept at
−80◦C for further analysis. The constructs were thawed at RT
and sonicated 20min to trigger the membrane lysis. The samples
were incubated 10min in the dark with fluorescent Picogreen R©
dye. The fluorescence of the supernatant was measured using
a microplate reader at 485 and 530 nm excitation and emission
wavelength, respectively. SF scaffolds without cells were used as
control. To calculate the DNA amount in each sample, the data
obtained from the assay were plotted together with the values of
DNA concentration and fluorescence of a standard curve ranging
between 0 and 2 µg/mL.
Statistical Analysis
To determine statistical significance, the data were analyzed using
GraphPad Prism v5.01 software (GraphPad Software, La Jolla,
CA). All statistics were reported as mean ± standard deviation.
One-way ANOVA test was used to compare the data, followed by
Tukey’s test. All the experiments were performed in triplicate and
statistical significance was considered at p<0.05.
RESULTS
The aim of this work is the development of an in vitro 3D breast
cancer model based on co-cultured primary normal human
mammary fibroblasts (HMF) and two different types of breast
cancer cells (MCF-7 and MDA-MB231). Two cell types were
chosen to mimic different stages of breast cancer like early
stage and invasive phenotypes. The chosen scaffold type is 2
wt% silk fibroin (SF) freeze-dried scaffolds of two thickness (1
or 2mm). The schematic representation (Figure 1) shows the
approach followed for the development of the 3D-BCM. Briefly,
normal mammary fibroblasts were seeded on the SF scaffold. At
day 7 of culture, breast cancer cells, MCF-7 and MDA-MB231,
respectively, were added into the fibroblast-laden scaffolds and
cultured until day 14. Mono-cultures (3D-HMF, 3D-MCF7, 3D-
231) were used as control to investigate how the interplay
between the cancer cells and fibroblasts could affect the tumor
growth or the response to Doxorubicin treatment.
Silk Fibroin Scaffold Preparation and
Characterization
Porous SF scaffolds of different thickness were obtained by
freeze-drying of different volumes of silk solution (2 wt%)
(Figures 2A,B). Figures 2B,C represent the side and top views,
respectively, which reveal highly porous interconnected nature
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FIGURE 2 | Silk fibroin (SF) scaffolds’ morphological characterization and diffusion. SF scaffolds are obtained pouring 50 µL and 100 µL of silk fibroin solution (2 wt
%) in a 96 TCPS well plate (A). Full side (A,B) and high view (200× magnification, scale bar 100µm) of SF 1 and 2mm scaffolds are shown, respectively. Micrographs
(C) show the surface profile of the SF scaffolds. The graphs represent the pore size distribution in the two types of SF scaffolds (1mm and 2mm). (D) The pore size
distribution is plotted in the graph. Micrographs (E) exhibit the interconnectivity of the porous network in the scaffold with the relative value (F) for the pore size, pore
wall thickness and inter-connectivity obtained by means of Micro CT analysis (n = 3). Alamar blue dye is used to demonstrate liquid diffusion within the scaffolds (G).
FIGURE 3 | Diffusion profile of doxorubicin (DOX) in the Silk fibroin (SF) scaffolds. DOX is loaded in the SF scaffold and the confocal images are shown together with a
DOX free scaffold. It is evident from the SF auto-fluorescence (A). Loading efficiency in both 1 and 2mm scaffolds is evaluated (B). Cumulative DOX release curve
represents the DOX release along 7 days, which is measured by mean of spectrophotometric technique (n = 3) (C).
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of SF scaffolds. The gradient distribution of pores across the
scaffold thickness was due to ice crystal formation and freeze-
drying process (Arya et al., 2012). The pore sizes obtained from
Micro CT were 43 ± 1 µm and 56 ± 1 µm, respectively
(Figure 2). The thickness of pore wall was decreased with
the increased pore size. Both the scaffolds exhibited well-
interconnectivity (> 95%) (Figure 2F). To further demonstrate
the pore interconnectivity, the SF scaffolds were rehydrated in
PBS and placed within a dish containing Alamar blue dye (Rnjak-
Kovacina et al., 2015). Instantly upon contact with Alamar blue
dye, the scaffolds appeared blue despite being hydrated in PBS
(Figure 2G). The uptake of dye readily by the scaffolds indicated
the interconnectivity within sponges. Figure 3A shows the
representative confocal microscopy images of porous SF scaffolds
with or without doxorubicin (DOX). In order to measure the
diffusion properties of scaffolds, the loading of DOX was carried
out (for easy visualization due to auto-fluorescence nature of
DOX). The diffusion of DOX immediately after immersion was
imaged (Figure 3A), which indicated the diffused fluorescence
signal throughout the porous scaffolds. However, the time-
dependent quantitative analysis of DOX diffusion into the porous
matrix was not possible to perform due to high loading efficacy.
The loading efficacy can be defined as the percentage amount
of DOX loaded/entrapped within porous silk fibroin scaffold
after initial exposure to free drug and was observed > 80%
for both sponges (Figure 3B) that corresponding to excessive
fluorescence signal (the autofluorescence of silk also provided
some background). The release of DOX from scaffolds was
defined in relation with their thickness. The release was relatively
slow for 2mm scaffolds, resulting a cumulative release of 89%
FIGURE 4 | Cell proliferation profile in 1 (A) and 2mm (B) Silk fibroin (SF) scaffolds. The cells proliferation is investigated at different time points (Day 1, 3, 7, 9, 14) for
both homotypic and heterotypic 3D-BCMs by mean of Alamar blue assay. *P < 0.05 is considered as statistically significant (n = 3).
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FIGURE 5 | Scanning electron micrographs of the developed 3D tumor models. 3D-HMF/MCF7 and 3D-HMF/231 in 1mm and 2mm SF scaffolds are fixed in 2.5%
glutaraldehyde at day 14 of co-culture. The scale bar is 10µm for the 1,500× magnification and 15µm for the 2,000× magnification micrographs.
after 7 days compared to 1mmones,∼93% (Figure 3C). For both
types of scaffolds the rapid release of DOX was observed over
the first 48 h and this was 73 and 63% of total cumulative release
from 1 or 2mm, respectively. The release was dropped over the
remaining period of study.
Cell Viability and Distribution Within Silk
Fibroin Scaffolds
Alamar blue assay was carried out to assess the viability and
metabolic activity of the cells within the scaffold at different time
point (Day 1, 3, 7, 9, 14). The metabolic activity of cells increased
along with the time when cells were cultured in both 1mm
and 2mm silk fibroin scaffolds. In both cases, the heterotypic
model showed a higher proliferation rate in comparison to the
homotypic one (Figure 4), with high growth peak at day 14
for 3D-HMF/MCF7 in 2mm SF scaffold. We do not observe a
significant difference in cell growth when the cells were seeded
in 1 or 2mm thickness scaffolds. The cells showed a rounded
shape in the SF scaffold according to the SEM micrographs
(Figure 5). The cell morphology and distribution were further
investigated by mean of Hematoxylin/Eosin staining. Both
SEM micrographs and micro-tumor sections revealed a 3D
rearrangement of the tumor cells in the scaffolds (Figure 6A).
The HMF/MCF-7 cells formed compact aggregate in the SF
scaffold resembling the 3D architecture of a tumor mass. The
HMF/MDAMB231 cells were more spread in the SF scaffolds
of both thicknesses (1mm and 2mm). Confocal images showed
the higher cellular density in the heterotypic 3D-BCM, which
also confirmed by the metabolic activities increments. HMF
maintained a more spread and elongated shape while the
cancer cells (MCF-7 and MDAMB-231) exhibited rounded
shape (Figure 6B). The Z-scanning of the constructs (i.e.
cell laden silk scaffolds of different thickness) indicated the
invasion of cells within the interconnective porous scaffolds.
Moreover, the cells penetrated both scaffolds irrespective of
their thickness. The morphology and dissemination of the cells
throughout the scaffolds were also confirmed by micrographs
from SEM observation.
Cytotoxicity of DOX in 3D-BCM
At day 15 of culture, the 3D-BCM were challenged with two
different concentrations of DOX (15 and 30µg/mL) as illustrated
by the experimental timeline (Figure 7A). The DOX cytotoxicity
against the 3D-BCM was evaluated at three different time
points (24, 48, 72 h). Cell metabolism was evaluated by mean
of Alamar Blue assay. In 1mm SF scaffold, we observed a
reduction of the cell metabolism in the 3D-HMF/MCF7 and
3D-HMF/231 co-culture in comparison to the respective 3D-
MCF7, 3D-231monoculture at day 14 (Figures 7B,C). Moreover,
it is interesting to observe that the 3D-HMF/231 metabolism
both in 1mm and 2mm SF scaffold was slightly higher than
the 3D-HMF/MCF7 one at the three time-points selected
for the analysis (Figures 7B–G). It is interesting to report
that we obtain a time/dose-related response when heterotypic
3D-BCM were treated with DOX at the concentration of
30µg/mL in the 2mm SF scaffold (Figures 7F,E). In the 2mm
SF scaffolds, the metabolic activity of the 3D-HMF/231 is
higher than the 3D-231 monoculture. Double-stranded DNA
content was evaluated after DOX treatment in co-cultures
(Figures 7D,E for 1mm scaffold and Figures 7H,I for 2mm SF
scaffolds) by mean of PicoGreen DNA assay. However, if the
percentage of DNA content is calculated, the reduction is not
strong when we compared the monocultures and cocultures in
1mm SF scaffolds (Figures 7D,E). The results demonstrated a
stronger reduction in DNA content when cells were cultured
in 2mm SF scaffolds in comparison to 1mm. The results were
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FIGURE 6 | Hematoxylin/eosin staining of developed 3D tumor models constructs at day 14 in both homotypic and heterotypic condition. (A) Shows representative
images of the 3D-BCM: tumor cells are arranged in spheroid-like architecture (3D-MCF7 and 3D-HMF/MCF7). MDAMB-231 cells spread along the scaffold and do
not show an acinar structure (Scale bar 50µm). (B) Representative image of nuclei and cytoskeleton, respectively, stained by DAPI (blue) and Phalloidin (red) (Scale
bar 100µm). The images showed a higher density of cells in heterotypic 3D-HMF/MCF7 and 3D-HMF/231. All the images refer to day 14 of cell culture.
also dose-dependent, showing more decrease in heterotypic
cultures in 2mm SF scaffolds treated with 30µg/mL of DOX
(Figure 7I). In 2mm SF scaffolds, the DNA content is higher
in cocultures than in monocultures (Figures 7H,I). If only
monocultures are considered, both cell metabolism and DNA
content decreased in 3D-MCF7, and 3D-231 cultured onto
1mm SF scaffold. Reduction in DNA content in 2mm SF
scaffolds was higher than in 1mm SF scaffold (Figures 7F–I).
The highest decrease in DNA content is reached when 3D-
231 in 2mm SF scaffold is challenged with 30µg/mL for 72 h
(Figure 7I).
Gene Expression Profiling in 3D in vitro
Breast Cancer Model
The expression of genes related to the tumor microenvironment
was analyzed. Gene expressions in tumor homotypic and
heterotypic cultures were normalized to the homotypic culture
of normal mammary fibroblasts (3D-HMF) (Figure S1). The
up-regulation of Col-I and Fibronectin in the 3D-HMF/MCF-
7 and 3D-HMF/231 in comparison to 3D-MCF-7 and 3D-
231, both in 1mm and 2mm thickness SF scaffolds, is quite
relevant. An interesting trend is observed for fibronectin
modulation: in 1mm SF scaffolds, fibronectin level is lower in
3D-HMF/231 when compared to 3D-HMF/MCF-7, while this
difference is not statistically significant in 2mm SF scaffold.
MMP-2 is upregulated in both 1mm and 2mm SF scaffolds,
where 3D-HMF/MCF-7 showed a higher fold change when
compared to 3D-HMF/231. In 1mm SF scaffold, we observed
a downregulation of MMP-1 and MMP-3 in co-cultures in
comparison to mono-culture, while MMP-2 expression is
higher in 3D-HMF/MCF-7 and 3D-HMF/231 in comparison to
mono-culture. Regarding the 2mm SF scaffold, the expression
of MMP-1, MMP-2, MMP-3, Col-1 and Fibronectin is slightly
higher in co-culture than in mono-culture. If we compare
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FIGURE 7 | DOX treatment on heterotypic 3D breast cancer model. (A) Schematic experimental workflow for the drug testing set-up. The DOX activity is evaluated at
24, 48, and 72 h, starting on day 14 of 3D culture. Anti-proliferative effects of DOX on 3D-MCF7 and 3D-HMF/MCF7 (B,F) and 3D-231 and 3D-HMF/231 (C,G) was
measured by mean of Alamar blue assay in 1 and 2mm SF scaffolds, respectively. Graphical representation of the amount of double stranded DNA (dsDNA) detected
in 3D-MCF7 and 3D-HMF/MCF7 as well as in 3D-231 and 3D-HMF/231 after 24, 48, and 72 h of DOX treatment [(D,E) for 1mm plus (H,I) for 2 mm SF scaffolds]. P
< 0.05 (*) is considered as statistically significant. **p < 0.01, ***p < 0.001 (n = 3).
the fold change of the MMP-1 and MMP3 expression in
3D-HMF/MCF-7 and 3D-HMF/231 is higher when the cells
were seeded onto 2mm thickness SF scaffolds in comparison to
1 mm ones.
DISCUSSION
Reliable 3D in vitro models can unravel cancer complexity,
since they may recapitulate the interactions among the cells of
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FIGURE 8 | Graphical summary of the experimental setting. Silk fibroin scaffolds are used as matrix to grow different breast cancer cells lines together with mammary
fibroblast. The 3D tumor models are challenged with doxorubicin to demonstrate the effect of tumor - stroma cells to the drug response.
the tumor microenvironment (Caballero et al., 2017; Ferreira
et al., 2018; Rodrigues et al., 2018; Brancato et al., 2020). The
pharmaceutical companies require novel approach to face the
lack of efficacy of the current models to assess the anti-cancer
agents (Hickman et al., 2014; Lovitt et al., 2016). The present
model aims to be a leap toward the adoption of 3D in vitro
model as platform for drug testing in the preclinical studies.
In this work, we propose a 3D-BCM (3D-breast cancer model)
where breast cancer cells and mammary normal fibroblasts
are seeded together on a tridimensional scaffold. Co-culturing
different types of cells gives the opportunity to analyze the
interaction between tumor and stroma counterpart. In this work,
we exploited the potential of silk fibroin frommulberry silkworm
as biomaterial to build a support for tumor cells growth. We have
developed an off-the-shelf scaffold that maintains its features
for long periods and the work has been focused to investigate
how the thickness of the scaffolds effects the re-creation of
tumor micro-niche and drug sensitivity (Figure 8). Natural silk
protein fibroin is an interesting and versatile biomaterial. The
process to obtain silk fibroin is straightforward and standardized,
which makes this biomaterial quite appealing for biomedical
applications (Kundu et al., 2014). Different matrices can be
obtained in aqueous solution. Fibroin is used for different
range of tissue engineering, regenerative medicine and stem cell
research applications, due to its certain important features being
protein biopolymer like robust mechanical properties, resilient,
biodegradable, low immunogenic response and biocompatibility
(Vepari and David Kaplan, 2007; Omenetto and Kaplan, 2010;
Kundu et al., 2014; Benam et al., 2015; Rnjak-Kovacina et al.,
2015; Pradhan et al., 2016; Yan et al., 2016; Holland et al.,
2019). For the fabrication of different scaffolds silk fibroin can
be used alone (Talukdar and Kundu, 2012) or in combination
with collagen (Khoo et al., 2019), chitosan (She et al., 2008),
gellan gum (Kundu et al., 2019) in order to fabricate scaffolds
and recapitulate the tumor microenvironment. In addition, the
natural source of fibroin is obtained from the mulberry silkworm
cocoons (Bombyx mori), which are available abundantly and
cost-effective in comparison to collagen or other exogenous
extracellular matrices used to prepare scaffolds. Silk fibroin is
widely used to fabricate in vitro different disease models (Kundu
et al., 2013a, 2019; Sitarski et al., 2018) including breast cancer
one (Wang et al., 2010; Talukdar and Kundu, 2012; Khoo et al.,
2019). The tunings of the certain properties like mechanical
and degradation are possible (Koh et al., 2015; Holland et al.,
2019) as well as the regenerations of different types of tissues
(Kundu et al., 2013b; Li et al., 2020). The porosity of the
scaffold allows the cancer cell to grow as cluster in a three
dimensional structure, resembling the tumor niche (Kundu et al.,
2019). Ice-crystals act as porogen during the preparation of
silk fibroin scaffolds. The large volume of solution takes more
time to freeze, imparting a relatively large crystal size in thicker
scaffolds (2mm) compared to thinner one (1mm). However, the
pore-micro-architecture of both scaffolds is in well-agreement
with the porous network of collagen-derived matrices, which
is popularly used to investigate breast cancer cells invasion
(Sapudom et al., 2015). The aforementioned study indicates least
impact of pore sizes onmorphology and behavior of breast cancer
cells in 3D. Interconnectivity of sponges is linked with cellular
distribution and is imparted by the interlocking phenomena of
ice-crystals during freezing of silk fibroin solution. By adjusting
the concentration of silk solution into designed biomaterials,
the release of the drug can be manipulated (Seib et al., 2013).
However, to our best of knowledge, this is the first report
depicting the different release of drugs based on the thickness
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of silk materials. The adsorption of doxorubicin is facilitated by
the hydrophobic core of silk as indicated by the binding affinity,
which in turn depends on crystallinity (Omenetto and Kaplan,
2010). Therefore, the higher the amount of β-sheet within the
porous silk sponges, greater is the loading efficacy and slower is
the release. This is observed in our present findings (Figure 3A).
Silk fibroin being autofluorescent in nature also appear green
in DOX free samples (Amirikia et al., 2018). The incorporation
of DOX increase the noise, leading to blur fluorescent images.
The systematic release of DOX from silk fibroin hydrogels is
previously investigated (Seib et al., 2013). It has indicated the
impact of weight percentage of silk on drug release. It suggests
that 2 wt % of silk provide the highest cumulative release.
Therefore, the choice of 2 wt % of SF sponge to model the
drug screening platform in the present study is rational. DOX
is considered as a model drug in the present study in order
to interpret the diffusion of therapeutic molecules through the
silk fibroin scaffold, which is further envisioned as low-cost
drug screening platform. However, the cross-reactivity of the
therapeutic molecules with silk fibroin is needed to be considered
and should be investigated systematically for each case.
In this model, commercially available human breast cancer
cells and mammary primary fibroblasts are seeded onto 1 or
2mm silk fibroin scaffolds. In particular, the human mammary
primary fibroblasts mimic the tumor stromal counterpart in
the 3D-BCM. Two breast cancer cell lines types (luminal and
basal phenotype) (Holliday and Speirs, 2011) are coupled with
normal fibroblasts in order to recapitulate different subtype of
breast cancer microenvironment. The proposed model is not
the first in terms of co-culture of tumor and stromal cells
(Wang et al., 2010; Hickman et al., 2014; Santo et al., 2016;
Brancato et al., 2017a; Dondajewska et al., 2018). However,
it shows that the heterotypic model is in the right roadmap
toward the fabrication of a functional and efficient 3D tumor
model. Other 3D tumor models based on solid porous scaffolds
do not take into account of the stromal component (Talukdar
and Kundu, 2012; Kundu et al., 2013a; Brancato et al.,
2017b). Recently, myofibroblasts or cancer activated fibroblasts
(CAF) are considered important player in triggering tumoral
progression (Beacham and Cukierman, 2005; Cirri and Chiarugi,
2012; Lovitt et al., 2016; Alguacil-Núñez et al., 2018). Fibroblasts
have dual role in tissues. In normal condition, fibroblasts protect
the tissues from the cancer cells invasion and proliferation (Werb
and Lu, 2016). In stress condition caused by wound or during
tumorigenesis, the paracrine loop between cancer cells and
fibroblasts triggers the stromal cells transformation, activating
the fibroblasts. This phenomenon is known as stromagenesis
and runs in parallel with the tumor progression (Castelló-Cros
and Cukierman, 2009; Lu et al., 2012; Werb and Lu, 2016).
The 3D-BCM proposed in this work is able to capture the
evolution of the tumor microenvironment from the initial step
where the cancer cells modify the tumor surrounding. Further
investigations should assess if the tumor microenvironment
transformation is due to the direct contact of the cells ormediated
by soluble factors. Our results in terms of cell proliferation
in the scaffold are aligned with other previous results where
the cells in the scaffolds are metabolically active during the
period of 14 days chosen for the model (Brancato et al., 2017a).
It is also noteworthy to highlight that the cells in homotypic
models are less proliferative when compared to the heterotypic
conditions. This shows an interaction among the cell type in
the promotion of cell viability and proliferation. Breast cancer
cells in the 3D scaffold show a rounded shape, and fibroblast
are less elongated than the usual morphology they exhibit in
2D culture. This is highlighted by the SEM and fluorescence
images. Histological staining shows that cancer cells copycat
the acinar spheroid-like structure. This morphological profile
has already recapitulated in previous works (Wang et al., 2010;
Talukdar and Kundu, 2012; Wang and Kaplan, 2012; Kundu
et al., 2013a). The spheroid architecture is the most resembling
tumor spatial organization in vivo. ECM secreted by CAF has
also a peculiar profile characterized by the over-expression of
MMP’s, Col I, and fibronectin among the others. Those genes
are hallmark for fibrotic phenotype in solid cancers (Bornstein
and Sage, 2002; Wong and Rustgi, 2013). Our results state the
overexpression of tumor microenvironment markers when the
fibroblasts are co-cultured with cancer cells. The up-regulation of
MMPs is extremely important features to recapitulate as they play
a relevant role in the remodeling of tumor microenvironment.
Moreover, our model showed that cancer cells could stimulate
the production of collagen by fibroblasts. The CAFs are also
investigated as target for anti-cancer agents due to their
sophisticated crosstalk between cancer cells and stroma (Zhuo
et al., 2009; Conklin and Keely, 2012; Quail and Joyce, 2013).
It has also been demonstrated that 3D in vitro tumor platform
recapitulate better the drug-response. This has been shown when
stroma or tumor microenvironment is included in the models
(Ridky et al., 2010; Peck and Wang, 2013; Lovitt et al., 2016;
Brancato et al., 2017c, 2018). In this work, the use of two different
thicknesses to fabricate 3D-BCM also affects the drug response.
Based on previous studies (Brancato et al., 2018; Dondajewska
et al., 2018) and considering the morphology and thickness of
the scaffolds, we selected two different DOX concentrations to
carry out our drug-response tests. We have found that 2mm SF
scaffold has retained DOX for a longer time and the release has
been slower as compared to the 1mm SF scaffold. The 2mm
scaffold’s behavior has affected the inhibition of proliferation and
metabolic activity after DOX treatment. It may be postulated that
DOX is entrapped in the scaffold for a longer period, whichmight
have been available for the cells during the 72 h of treatment.
The differences in DOX release may be referred to the size of
scaffold and the capability to embed more liquid solution. In
our opinion, the scaffold thickness is relevant to recapitulate the
tumor microenvironment and to make the drug-screening tool
more reliable. In this work, the 2mm scaffold can be considered
the best choice for further investigation because allows a slower
DOX release and it is able to reduce the cellular metabolic
activity and proliferation, better than the 1mm SF scaffold. 3D-
BCM proposed in this work is suitable for drug screening. This
model may also support the possibility to perform proliferation
assays as well as an easy histological sample preparation along
with the gene expression analysis. These are strong advantages
of this model toward further characterization for the use as
testing platform for anti-cancer drug screening. Bioengineered
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cancer models are a valid support to preclinical studies. In
this work, we demonstrate that heterotypic 3D in vitro cancer
model may unravel the crosstalk between cancer cells and tumor
microenvironment. We consider that the sample size of the
experimental set-up is less, however, previous works demonstrate
the reproducibility of the results when SF freeze-dried matrices
are used (Talukdar and Kundu, 2012; Kundu et al., 2013a). In
future, other cancer types characterized by a fibrotic stroma can
be recapitulated using SF scaffolds as lung, colon or pancreatic
cancer. The system can be improved by adding endothelial or
immune cells in order to investigate the complexity of the tumor
microenvironment. In the near future, patient-derived cancer
and stromal cells can be seeded onto silk fibroin scaffold to
fabricate a 3D-BCM for personalized drug testing. In conclusion,
the developed 3D breast cancer model makes closer for the
complete understanding of the mechanisms underpinning breast
cancer progression.
CONCLUSION
The proposed in vitro breast cancer model aims to be used
as a tool for drug screening or for investigating tumor
microenvironment. Silk protein fibroin scaffold allows us to
grow both fibroblasts and cancer cells, which can facilitate
the investigation of the tumor-stroma crosstalk as well as cell-
extracellular matrix interactions. These interactions are necessary
for tumor growth and invasion. This model enlightens the
mechanism of tumor migration, cancer associated fibroblast
transformation and extracellular matrix remodeling. The model
is also a straightforward 3D platform for drug testing due to
its easy-to-use and cost-effective features. The interconnectivity
and stability of the platform is envisioned to study the invasion
of cancer cells over prolong time. The 3D breast cancer model
proposed may also be useful for better understanding of the
mechanisms behind chemoresistance and metastatic spread.
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